焦虑:医药CSO转型陷入「合规」困境!

2017-06-20 佚名 新浪医药新闻

先说下行业两位大咖对CSO的观点(主要是为了震场):刘三检:培训或是教别人开CSO,都是犯罪!刘谦:CSO有前途,但忽悠的多!一个是说你们都在犯法,一个是说骗子多,但前途还是有的。我个人比较赞成刘谦老师的观点:骗子多!有前途!为啥呢?1、政策不抵制CSO,刘三检老师的观点就不成立。目前,CSO全国开花,从很多省份的过渡期可看出,国家是允许行业自找出路的。ZF出政策,并不是为了让大家饿死,而是让大家

先说下行业两位大咖对CSO的观点(主要是为了震场):

刘三检:培训或是教别人开CSO,都是犯罪!

刘谦:CSO有前途,但忽悠的多!

一个是说你们都在犯法,一个是说骗子多,但前途还是有的。

我个人比较赞成刘谦老师的观点:骗子多!有前途!

为啥呢?

1、政策不抵制CSO,刘三检老师的观点就不成立。

目前,CSO全国开花,从很多省份的过渡期可看出,国家是允许行业自找出路的。ZF出政策,并不是为了让大家饿死,而是让大家光明正大的吃饭嘛。目前还没有政策说不让你办CSO。

2、除了CSO,你也没得选了。(不要说CSP啥的,实质上都是这个模式。)

从已经执行两票制的省份来看,转型无非就两个模式:

A、厂家多扣点位进行返现。

B、代理商自建CSO体系,财税票合理出来。

代理商找到税收洼地,注册个人的医药推广小规格公司,年开票不要高于500万。就能不做账轻松提现。

想想是美好的,回归现实来讲,现在,厂家虽没有要求返款的票从哪里来,款就要回哪里去,但未来肯定会。所以找票的行为绝对不可行了。

另一个是,有本事的厂家会辅助一段时间,但是有风险啊。为了规避风险,厂家未来会选择部分自己做直营,其他的要求自己转型。

3、为了活下来,不惜拿钱试错。

举一个比较夸张的例子给大家,2017年初,一个陕西的厂家老总,带着财务总监、销售总监,参加了一次CSO培训,3星级酒店4天3夜,培训费76万。当他说起时,一脸的耻辱!

我们都清楚的知道行业在洗牌,要想留下来,必然是先解决财税的问题,所以CSO才遍地开花。就有一些人抓住了这个需求点,到处去给大家培训如何开CSO公司:

怎样注册医药CSO公司

医药CSO注册什么类型

如何成立CSO医药公司

纵观整个做咨询培训的行业,大多都不是什么行业人士,没有实操过市场的专家。就像算命先生,他都能算出你啥时候发财,他咋就算不了自己的。所以,纯粹的忽悠。

为什么这么多人上当呢?因为行业吃政策饭,你不爬起来翻个身,政策这辆火车就要从你身上开过去了。

4、向左转型、向右淘汰,始终游走在法律边缘!

假如,

你已经注册CSO公司了,财税也搞定了。

你可能会问,我转型成功了吧?

我只能说,你也忒天真了!就如刘谦老师的观点,CSO有前途,但CSO并不是注册公司解决财税,你就高枕无忧。

你和厂家签订了什么业务合同?

你去执行合同了吗?

你有执行的业务人员吗?

你有证据链吗?

如果没有,你就是违法了!

想想刘三检老师

培训或是教别人开CSO,都是犯罪!

加上这样的一个前提,这句话就非常有道理。

以往被查,厂家都是被抓的重点!

现在,税务稽查局会通过金税三期系统的预警和人员举报来确定重点稽查对象!

如果不小心查到你了,

民事责任:转型CSO之后,你属于厂家的“正规”合作商,你如果没有按照合同执行业务,你属于违约,有民事责任,可能涉及对厂家赔偿。

刑事责任:你没有真实业务虚开发票,对于社会和公众要负刑事责任,直接坐牢。

而现在,整个医药行业都在这么操作。

合规!这是一个巨大的隐形炸弹!

(以上这段,欢迎法律专家拍砖)

为什么CSO徒有其表?

A、代理商思维没有转变,依然还在考虑开票提现的操作。

B、代理商没有人员可以去执行CSO的业务,如会议、调研等。

C、厂家按销量和代理商结算费用,代理商做合规成本高,没有意义。(根本原因)

D、刻意做合规的证据链,属于高级洗钱!

综上所述可见,80%的医药人走在财税需求阶段,20%的医药人开始实操业务证据链!

这就是我今天想说的,没有业务合规,我们离真正的CSO,还有十万八千里!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720644, encodeId=43a41e20644a8, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5355, encryptionId=92f8535575, topicName=CSO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c6132907836, createdName=mgqwxj, createdTime=Sun Sep 24 19:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707203, encodeId=46431e072034d, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sun Nov 05 14:52:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690190, encodeId=13b21690190cd, content=<a href='/topic/show?id=9237388e98a' target=_blank style='color:#2F92EE;'>#合规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38879, encryptionId=9237388e98a, topicName=合规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83b28990753, createdName=ms3046638856685384, createdTime=Sat Apr 07 12:52:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408961, encodeId=c04214089619b, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 22 11:52:00 CST 2017, time=2017-06-22, status=1, ipAttribution=)]
    2017-09-24 mgqwxj
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720644, encodeId=43a41e20644a8, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5355, encryptionId=92f8535575, topicName=CSO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c6132907836, createdName=mgqwxj, createdTime=Sun Sep 24 19:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707203, encodeId=46431e072034d, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sun Nov 05 14:52:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690190, encodeId=13b21690190cd, content=<a href='/topic/show?id=9237388e98a' target=_blank style='color:#2F92EE;'>#合规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38879, encryptionId=9237388e98a, topicName=合规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83b28990753, createdName=ms3046638856685384, createdTime=Sat Apr 07 12:52:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408961, encodeId=c04214089619b, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 22 11:52:00 CST 2017, time=2017-06-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720644, encodeId=43a41e20644a8, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5355, encryptionId=92f8535575, topicName=CSO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c6132907836, createdName=mgqwxj, createdTime=Sun Sep 24 19:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707203, encodeId=46431e072034d, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sun Nov 05 14:52:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690190, encodeId=13b21690190cd, content=<a href='/topic/show?id=9237388e98a' target=_blank style='color:#2F92EE;'>#合规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38879, encryptionId=9237388e98a, topicName=合规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83b28990753, createdName=ms3046638856685384, createdTime=Sat Apr 07 12:52:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408961, encodeId=c04214089619b, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 22 11:52:00 CST 2017, time=2017-06-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720644, encodeId=43a41e20644a8, content=<a href='/topic/show?id=92f8535575' target=_blank style='color:#2F92EE;'>#CSO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5355, encryptionId=92f8535575, topicName=CSO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c6132907836, createdName=mgqwxj, createdTime=Sun Sep 24 19:52:00 CST 2017, time=2017-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707203, encodeId=46431e072034d, content=<a href='/topic/show?id=fedc406085d' target=_blank style='color:#2F92EE;'>#困境#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40608, encryptionId=fedc406085d, topicName=困境)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a4631370697, createdName=ms2536978994064944, createdTime=Sun Nov 05 14:52:00 CST 2017, time=2017-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690190, encodeId=13b21690190cd, content=<a href='/topic/show?id=9237388e98a' target=_blank style='color:#2F92EE;'>#合规#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38879, encryptionId=9237388e98a, topicName=合规)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c83b28990753, createdName=ms3046638856685384, createdTime=Sat Apr 07 12:52:00 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408961, encodeId=c04214089619b, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jun 22 11:52:00 CST 2017, time=2017-06-22, status=1, ipAttribution=)]
    2017-06-22 cathymary